Skip to main content

Crohn's Disease Research Studies

Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people.

Investigators

5139-Bohm, Matthew

Matthew Bohm, BA, DO

Assistant Professor of Clinical Medicine

Read Bio

4964-Fischer, Monika

Monika Fischer, MD

Associate Professor of Medicine

Read Bio

5125-Sagi, Sashi

Sashi Sagi, MBBS

Assistant Professor of Clinical Medicine

Read Bio

Open Research Studies for Crohn's Disease

Diversity

Enrolling: Yes

Principle Investigator: Matthew Bohm, MD

Duration: 32-66 weeks + Long-term Extension (Approx. 8-13 clinic visits)

Patient Population:  Adult patients with moderately to severely active Crohn’s disease

Study Intervention:  Filgotinib (Oral)

Possibility of Placebo:  1 in 3

Galaxi

Enrolling: Yes

Principle Investigator: Sashidhar Sagi, MD

Duration: 48 weeks + potential to receive up to 2 additional years of treatment

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention:  Guselkumab or Ustekinumab  ( IV + Subcutaneous)

Possibility of Placebo:  1 in 5

Yellowstone

Enrolling: Yes

Principle Investigator:  Monika Fischer, MD

Duration: 12 Weeks + potential to receive treatment for up to 4.5 years

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention:  Ozanimod (Oral)

Possibility of Placebo: 1 in 3

SPARC IBD

Enrolling: On Hold

Principle Investigator:  Matthew Bohm, DO

Duration:  All bio-specimen collections and chart reviews will continue until 2026

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Intervention:  Medical chart reviews and biological specimen collection.

VIVID - 1

Enrolling: Yes

Principle Investigator:  Monika Fischer, MD

Duration: 1 year – Option to roll into the long term extension study VIVID-2

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention:  Mirikizumab vs Stelara vs Placebo

Possibility of Placebo: 2 in 11

IBD QORUS

Enrolling: By the end of 2020 

Principle Investigator:  Sashidhar Sagi, MD

Duration:  Indefinate or upon withdraw

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Procedures:  Patient surveys before every office visit & medical chart reviews

Lattice

Enrolling: November 2020

Principle Investigator:  Monika Fischer, MD

Duration: Approximately 112 weeks

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention:  BMS-986165 (oral)

Possibility of Placebo: 1 in 4